FDA Section 361 HCT/P Donor Screening Verification Checklist

An FDA Section 361 HCT/P donor screening verification checklist for buyers provides practice managers and purchasing clinicians with a structured procurement audit framework to verify 21 CFR Part 1271 donor eligibility, communicable disease screening, and tissue establishment registrations before intake. By systematically auditing Donor Risk Assessment Interviews (DRAI) and CLIA laboratory testing results prior to order acceptance, practices mitigate regulatory liability and protect patient safety. Implementing this intake verification protocol ensures your clinical team maintains complete compliance and regulatory traceability for all incoming biologics.

Understanding FDA Section 361 Requirements for Biologics

Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) fall under Title 21 of the Code of Federal Regulations (CFR), Part 1271. To qualify for regulation solely under Section 361 of the Public Health Service (PHS) Act—rather than being regulated as a drug, device, or biological product under Section 351—an HCT/P must satisfy specific statutory criteria. Specifically, the product must be minimally manipulated, intended for homologous use, and must not depend on the metabolic activity of living cells for its primary function (unless intended for autologous use or specific reproductive/allogeneic relative uses).

For practice administrators purchasing biologics, maintaining regulatory compliance requires verifying that the manufacturer or tissue processor adheres strictly to Subpart C (Donor Eligibility) and Subpart D (Current Good Tissue Practice, or cGTP) of 21 CFR 1271. A failure in donor screening or infectious disease testing at the processing level creates substantial clinical, ethical, and legal vulnerability for the receiving practice.

FDA Section 361 HCT/P Donor Screening Verification Checklist

Before adding any allogeneic tissue product to your active inventory, your procurement team should complete a standardized audit of the tissue bank’s documentation. Use the following checklist to evaluate donor eligibility files, testing protocols, and lot-specific documentation:

1. Donor Screening and History Protocols

• Completed Donor Risk Assessment Interview (DRAI): Verify that the tissue donor underwent a comprehensive behavioral, medical, and social history screening adhering to AATB (American Association of Tissue Banks) standards and FDA guidance.
• Prenatal & Maternal Screening (for Birth Tissues): Confirm full review of maternal medical records, prenatal laboratory panels, delivery charts, and OB/GYN clearance prior to recovery.
• Exclusionary Criteria Audit: Ensure explicit screening out of high-risk behaviors, systemic infectious diseases, neurodegenerative disorders, autoimmune conditions, and active malignancies.

2. Mandatory Infectious Disease Testing Verification

• CLIA-Certified Testing Facilities: Confirm that all donor blood specimens were evaluated in laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) and registered with the FDA.
• FDA-Cleared Screening Assays: Verify the use of FDA-cleared donor screening assay kits for the following required communicable disease markers:
• Human Immunodeficiency Virus, Type 1 and Type 2 (HIV-1/2 antibody and HIV-1 Nucleic Acid Test [NAT])
• Hepatitis B Virus (HBsAg and total anti-HBc, along with HBV NAT)
• Hepatitis C Virus (anti-HCV and HCV NAT)
• Human T-Lymphotropic Virus, Types I and II (anti-HTLV-I/II)
• Treponema pallidum (Syphilis screening)
• Cytomegalovirus (CMV total/IgM testing, where applicable for clinical suitability)
• West Nile Virus (WNV NAT, as seasonally or geographically mandated)

3. Lot-Specific Certificate of Analysis (CoA) & Traceability

• Matching Lot Numbers: Ensure the lot number on the physical vial or package match the accompanying Certificate of Analysis and Certificate of Conformance exactly.
• Sterility Assurance Level (SAL): Confirm validated terminal sterilization or aseptic processing verification (typically achieving SAL 10^-6 or rigorousUSP <71> sterility testing protocols).
• Endotoxin Testing: Verify that bacterial endotoxin levels are tested (USP <85>) and fall below established clinical thresholds (e.g., <20 EU/device or USP limits for intra-articular or topical applications).
• Chain of Custody Tracking: Ensure a clear tracking record from recovery agency to tissue processor to distributor and receiving clinic.

4. Vendor and Processor Regulatory Registration

• FDA Establishment Registration: Confirm that the primary tissue processor holds an active FDA Establishment Registration (Form FDA 3356) and is listed in the FDA HCT/P database.
• State Tissue Bank Licensing: Verify state-level licensure where required (e.g., Texas, California, Florida, New York, or Maryland tissue bank licenses).

Clinical Perspective: Patient Safety and Allograft Integrity

For regenerative medicine doctors and treating clinicians, donor screening verification is fundamental to clinical safety and patient trust. Clinicians must be confident that the tissue products introduced into musculoskeletal, dermal, or surgical sites are free from pathogens, non-pyrogenic, and structurally intact.

Evaluating the processor’s screening protocols allows clinicians to answer patient questions regarding allograft origin with absolute transparency. Beyond infectious disease clearance, clinicians should review how processing methods (e.g., dehydration, lyophilization, cryopreservation, or ambient preservation) impact matrix structure, growth factors, and extracellular components without compromising safety. Integrating donor verification directly into clinical workflows ensures that product selection aligns with sound evidence-based practice.

Operational Perspective: Inventory Control, Record Retention, and Risk Management

From a practice management standpoint, receiving HCT/P inventory without verified documentation creates severe operational risks. Under 21 CFR 1271, tissue recordkeeping mandates that medical facilities maintain comprehensive records for a minimum of 10 years beyond the date of administration or expiration.

Practice managers must establish intake Standard Operating Procedures (SOPs) that prevent inventory from entering clinical storage until the accompanying CoA and donor eligibility summary are logged and cross-referenced. In the event of an FDA audit or a vendor recall, the clinic must be capable of tracing a specific lot number back to the exact recipient patient within hours. Implementing robust inventory software or physical compliance binders for every biologics delivery reduces liability and prevents costly administrative delays.

What This Means for Your Practice

To ensure your facility remains fully compliant and protected against procurement liabilities, take the following immediate actions:

1. Establish a Standard Receiving SOP: Require administrative staff to quarantine incoming allografts until the lot-specific CoA and donor eligibility records are reviewed and signed off.
2. Audit Current Vendors: Request updated FDA Form 3356 registration documents, state licenses, and sample CoAs for every HCT/P line currently stocked in your clinical freezer or ambient storage.
3. Centralize Compliance Records: Archival systems must be organized for rapid retrieval. Maintain digital or hard-copy compliance files sorted by lot number, maintaining records for at least 10 years.
4. Train Procurement Personnel: Ensure office managers and clinical assistants understand how to read a CoA, recognize missing test panels, and verify thermal indicator flags on incoming shipments.

For additional context on regulatory protocols and vendor compliance frameworks, review our answers to common compliance questions on our FAQ page.

Streamlining Biologics Procurement with Compliant Verification

Navigating the regulatory landscape of human cells, tissues, and cellular products requires meticulous oversight, but it should not slow down clinical operations. Partnering with experienced distributors who enforce strict regulatory vetting streamlines inventory procurement while prioritizing patient safety.

To discuss compliance protocols, examine sample verification documentation, or consult on integrating fully vetted biologic solutions into your practice, contact Dallas Regenerative Solutions to speak with a specialist.